Our data indicate that (i), ETS-1 is not a downstream target of MEK/ERK pathways in cisplatin-resistant HNSCC, and (ii), other potential kinases can phosphorylate ETS-1-T38 in these cells. This evidence concerns the gene ETS1 and head and neck squamous cell carcinoma.